Specialty Pharma Journal Specialty, Precision & Technology
Darmstadt, Germany, and New York, US, December 21, 2018 – Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study’s initial hypothesis, and therefore the alliance made …
Tag Archives: avelumab
December, 2018
November, 2018
-
19 November
Avelumab Fails to Meet Primary Endpoints in Late-Stage Platinum-Resistant/Refractory Ovarian Cancer Trial
Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival (OS) or progression-free …
-
16 November
Immunicum Collaborates with Merck KGaA and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study
Immunicum AB (publ; IMMU.ST) announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial. …
-
7 November
Nektar and Pfizer Collaborate to Evaluate Combination of NKTR-214 with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ — Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN). The collaboration will evaluate Nektar’s lead immuno-oncology …
December, 2017
-
21 December
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with Inlyta in Advanced Renal Cell Carcinoma
DARMSTADT, Germany and NEW YORK, December 21, 2017 /PRNewswire/ — Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] Javelin Renal clinical development program is ongoing, including Phase III first-line study Merck and …
-
20 December
Array BioPharma and Pfizer Collaborate on Novel Anti-Cancer Combinations
BOULDER, Colo., Dec. 19, 2017 /PRNewswire/ — Array BioPharma (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel anti-cancer combinations, including Array’s MEK inhibitor, binimetinib, with Pfizer’s investigational PARP inhibitor talazoparib, and avelumab*, a …
November, 2017
-
28 November
Pfizer and Merck KGaA’s Avelumab Fails to Meet Primary Endpoint in Late-Stage Gastric Cancer Trial
Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Gastric 300 trial did not meet its primary endpoint of superior overall survival (OS) with single-agent avelumab* compared with physician’s choice of chemotherapy. The trial investigated avelumab as a third-line treatment for unresectable, recurrent …
May, 2017
-
9 May
FDA Approves Pfizer’s Bavencio for Treatment of Patients with Advanced Bladder Cancer
ROCKLAND, Mass. and NEW YORK, May 9, 2017 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection for the treatment of patients …
November, 2016
-
30 November
FDA Grants Priority Review to Avelumab for Treatment of Merkel Cell Carcinoma
EMD Serono Inc., the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review EMD Serono’s Biologics License Application (BLA) for avelumab. This review relates to avelumab’s proposed …
October, 2016
-
12 October
Transgene Collaborates with Merck and Pfizer for Head and Neck Cancer Trial
Strasbourg, France, October 11, 2016, 6:00 pm CET – Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced it has entered a collaboration agreement with Merck, the science and technology company, and Pfizer (NYSE: PFE) under …